AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at Wedbush cut their FY2019 EPS estimates for AnaptysBio in a report released on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($3.01) per share for the year, down from their previous estimate of ($2.95). Wedbush currently has a “Positive” rating and a $82.00 target price on the stock. Wedbush also issued estimates for AnaptysBio’s FY2020 earnings at ($3.15) EPS and FY2021 earnings at ($1.85) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/brokers-issue-forecasts-for-anaptysbio-inc-s-fy2019-earnings-anab/1691124.html.

Other analysts also recently issued research reports about the company. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Wednesday, August 30th. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 12th. Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group LLC initiated coverage on AnaptysBio in a research note on Thursday. They set a “buy” rating and a $101.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $76.25.

Shares of AnaptysBio (ANAB) traded up $0.73 during trading on Thursday, reaching $66.32. The company had a trading volume of 247,300 shares, compared to its average volume of 481,336. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $74.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 11.50 and a current ratio of 11.50.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the sale, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. DAFNA Capital Management LLC raised its stake in shares of AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,000 shares during the period. New York State Common Retirement Fund grew its holdings in shares of AnaptysBio by 21.4% in the 3rd quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 1,500 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 1,807 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of AnaptysBio by 10.0% in the 3rd quarter. Alps Advisors Inc. now owns 20,034 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 1,824 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 1,951 shares in the last quarter. 59.40% of the stock is currently owned by hedge funds and other institutional investors.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.